PCN11 COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS AFTER FIRST-LINE FAILURE OF IMATINIB IN CHRONIC MYELOID LEUKEMIA (CML) IN AUSTRIA
Nov 1, 2007, 00:00 AM
10.1016/S1098-3015(10)65169-8
https://www.valueinhealthjournal.com/article/S1098-3015(10)65169-8/fulltext
Section Title :
Section Order :
328
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)65169-8&doi=10.1016/S1098-3015(10)65169-8